Gehaftes Auftreten der Immunthyreoiditis bei Patienten mit chronischer Polyarthritis

Pongratz, R.; Buchinger, W.; Semlitsch, G.; Meister, E.; Nadler, Karin; Rainer, F.

doi:10.1046/j.1563-2571.2000.00209.x

Cited by 10 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of AITD among patients with RA in our study, approximately 10% at diagnosis, is in line with previous studies. 6,8,13 The criteria for AITD, however, differ between studies, which, apart from the timing of the measurement, may be one explanation for the wide range of previously reported estimates of prevalence. 14,21 The timing of risk development seen in our study with an…”

Section: Results In Contextmentioning

confidence: 99%

“…Lead-time bias would not explain the previously reported increased occurrence of thyroid antibodies in patients with RA. 7 , 8 , 12 , 13 , 14 Besides lead time, the observed peak in risk of AITD shortly prior to diagnosis of RA may also reflect a possible critical causal link between the 2 autoimmune conditions, with one (AITD) triggering the clinical onset of the other (RA) in genetically predisposed individuals. Such a mechanism may explain the higher incidence seen among seropositive patients compared with seronegative patients, for whom there should not be any difference in diagnostic intensity or lead-time bias.…”

Section: Discussionmentioning

confidence: 99%

“…Most previous studies describing the association between AITD and RA have used crosssectional designs, and they have reported an increased prevalence of RA among patients with AITD, [9][10][11] an increased prevalence of AITD among patients with RA, 8,11 or an increased prevalence of thyroid autoantibodies in patients with RA. 7,8,[12][13][14] Although they demonstrate the co-occurrence of RA and AITD, these studies do not provide information on the risk of developing these conditions over time. Two studies of incident RA suggest that the increased occurrence of AITD may already exist by the time of the diagnosis of RA, raising the question of when this increased risk develops.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Risk of Thyroxine-Treated Autoimmune Thyroid Disease Associated With Disease Onset in Patients With Rheumatoid Arthritis

et al. 2018

View full text Add to dashboard Cite

Importance Autoimmune thyroid disease ([AITD] including hypothyroidism and hyperthyroidism) is the most common organ-specific autoimmune disorder and is more prevalent among patients with rheumatoid arthritis (RA). Real-world studies on when and how this increased risk of AITD develops, in association with the time before or after the onset of RA, are lacking. Objective To estimate the risk of thyroxine-treated AITD among patients with RA at different time points before and after the diagnosis of RA. Design, Setting, and Participants A nationwide register-based case-control and cohort study was conducted between January 1, 2006, and June 30, 2013, with a maximum follow-up time of 7 years before and 8 years after diagnosis of RA. The study used the Swedish Rheumatology Quality Register and linkage to other nationwide registers to identify 8090 adults with new-onset RA and a random population-based sample of 80 782 referents matched by age, sex, and residential area. Statistical analysis was performed from July 1, 2015, to June 30, 2017. Exposures Presence of AITD in the participants in the case-control design and RA in the participants in the cohort design. Main Outcomes and Measures Prevalence and relative risk of incident AITD before (odds ratios) and after (hazard ratios) diagnosis of RA compared with the population as reference. Results There were 8090 patients with RA (5529 women and 2561 men; mean [SD] age, 58.3 [15.2] years) and 80 782 population-based participants as reference who were identified. By the time of diagnosis of RA, the prevalence of AITD was 10.3% among the patients with RA (n = 832) vs 7.1% among the controls (5725 of 80 350) (odds ratio, 1.5; 95% CI, 1.4-1.7). This increased risk of AITD developed during the 5 years (range, 2-5 years) before diagnosis of RA (odds ratio, 1.5; 95% CI, 1.2-1.8) and peaked by the time of diagnosis of RA (range, 0-3 months before diagnosis of RA) (odds ratio, 5.3; 95% CI, 3.7-7.6). From diagnosis of RA and onward, the risk of developing AITD decreased (range, 2-5 years after diagnosis of RA) (hazard ratio, 0.7; 95% CI, 0.5-1.0). Conclusions and Relevance Compared with the general population, Swedish patients with RA appear to have a higher prevalence of thyroxine-treated AITD at diagnosis of RA and an increased incidence of AITD during the 5-year period before diagnosis of RA. After diagnosis of RA, the risk of developing AITD is suggested to decrease below the expected rate. Besides temporal changes in diagnostic intensity, this pattern of risk raises the question whether AITD may influence the pathogenesis of RA (or vice versa) and, conversely, the question whether antirheumatic therapies may prevent AITD.

show abstract

Section: Results In Contextmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk of Thyroxine-Treated Autoimmune Thyroid Disease Associated With Disease Onset in Patients With Rheumatoid Arthritis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The prevalence in RA cases ranged from 0.5% in Morocco [58] to 27% in Slovakia [71]. Within the studies analyzed, 10 studies were from Europe [23, 63–71] with prevalence ranging from 1% in Germany [65] to 27% in Slovakia [71]. Four studies were from the North American region [59–62] where prevalence ranged from 2.1% [61] to 9.8% [60].…”

Section: Resultsmentioning

confidence: 99%

Autoimmune Thyroid Disease in Rheumatoid Arthritis: A Global Perspective

et al. 2012

View full text Add to dashboard Cite

Objective. To determine the prevalence and impact of autoimmune thyroid disease (AITD) in patients with rheumatoid arthritis (RA). Methods. Eight-hundred patients were included. The association between AITD and RA was analyzed was analyzed by bivariate and multivariate analysis. In addition, a literature review was done focusing on geographical variations. Results. In our cohort the prevalence of AITD was 9.8% while the presence of antibodies was 37.8% for antithyroperoxidase enzyme (TPOAb) and 20.8% for antithyroglobulin protein (TgAb). The presence of type 2 diabetes, thrombosis, abnormal body mass index, and a high educational level was positively associated with AITD. The literature review disclosed a geographical variation of AITD in RA ranging from 0.5% to 27%. Autoantibody prevalence ranges from 6% to 31% for TgAb, 5% to 37% for TPOAb, and from 11.4% to 32% for the presence of either of the two. Conclusion. AITD is not uncommon in RA and should be systematically assessed since it is a risk factor for developing diabetes and cardiovascular disease. These results may help to further study the common mechanisms of autoimmune diseases, to improve patients' outcome, and to define public health policies. An international consensus to accurately diagnose AITD is warranted.

show abstract

“…[26] Some others have called this a manifestation of rheumatoid arthritis. [27] Among the most important or frequent rheumatic manifestations, there are a mild non-erosive variety of arthritis, polyarthralgia, myalgia, and sicca syndrome without a true Sjögren's syndrome. [28] In our patients, 16 (8.6%) had associated rheumatoid arthritis [Table 1].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of systemic lupus erythematosus among patients of hypothyroidism in a tertiary care center

Paul

Raychaudhuri

Sinha

et al. 2012

Indian J Endocr Metab

View full text Add to dashboard Cite

Context:Hypothyroidism is a common public health problem in India. With iodine sufficiency, autoimmune thyroiditis is becoming the most important etiology of hypothyroidism. Often, thyroiditis is associated with other systemic autoimmune diseases.Aims:We undertook thisobservational study to find the prevalence of systemic lupus erythematosus (SLE) amongst the hypothyroid patients at our Institution.Settings and Design:This is probably the first study of its kind from India.Materials and Methods:185 patients with diagnosed hypothyroidism were included and screening for SLE was done by standard epidemiological criteria. Majority of the patients (63.8%) were young adults (20-40 years).Statistical Analysis Used:Two by two contingency tables were analyzed by Chi-square test or Fisher's exact test as needed. Logistic regression model was used considering the presence of SLE as a dependent variable.Results:Eleven (5.94%) patients were found to have SLE. However, anti nuclear factor was positive in 145 cases (78.4%). Of the patients with SLE, 8 (72.7%) were found to be anti TPO positive, but the titers of ANF and anti TPO did not correlate. Presence of discoid rash, haematological criteria and presence of antibodies like anti-dsDNA were significantly correlated with the presence of SLE in hypothyroid patients. Presence of ANF was also correlated with the grade of goiter (r=0.62; P<0.05). Also four patients with SLE had a positive family history (OR=9.37). Logistic regression model showed anti-TPO has OR=1.54 (P=0.02) for the development of SLE.Conclusions:Prevalence of SLE in hypothyroid patients is high compared to the general population, especially, as thyroiditis is very common in SLE.

show abstract

Gehaftes Auftreten der Immunthyreoiditis bei Patienten mit chronischer Polyarthritis

Cited by 10 publications

References 0 publications

Risk of Thyroxine-Treated Autoimmune Thyroid Disease Associated With Disease Onset in Patients With Rheumatoid Arthritis

Risk of Thyroxine-Treated Autoimmune Thyroid Disease Associated With Disease Onset in Patients With Rheumatoid Arthritis

Autoimmune Thyroid Disease in Rheumatoid Arthritis: A Global Perspective

Prevalence of systemic lupus erythematosus among patients of hypothyroidism in a tertiary care center

Contact Info

Product

Resources

About